Galidesivir
- Generic Name
- Galidesivir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15N5O3
- CAS Number
- 249503-25-1
- Unique Ingredient Identifier
- OLF97F86A7
- Background
Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. In vitro, it displayed broad-spectrum antiviral activity against various negative- and positive-sense RNA viruses, including coronaviruses, filoviruses, and arenaviruses. Phase 1 clinical trials have begun to determine the safety of this drug in humans. Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03891420
- Locations
- 🇧🇷
Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Parana, Brazil
🇧🇷Foundation Regional Faculty of Medicine of São José do Rio Preto, São José Do Rio Preto, SP, Brazil
🇧🇷Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das ClÃnicas, School of Medicine, USP, São Paulo, SP, Brazil
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03800173
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.